Pralsetinib | List of Frontiers open access articles

Case Report

Published on 08 Dec 2022

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

in Cancer Molecular Targets and Therapeutics

Li An
Pengzhi Chen
Junfeng Wang
Xuebing Qin
Tingting Liu
Yanhong Gao
Peng Wang
Dong Zhang
Xiangqun Fang
Zhijian Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1024365

3,047 views
7 citations

Case Report

Published on 27 Feb 2025

Re-challenging pralsetinib following recovery from pneumocystis jirovecii pneumonia in a lung cancer patient: a Case Report

in Respiratory Pharmacology

Zhe Zhao
Longbin Pang
Surui Liu
Jie Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1443609

3,146 views
1 citation

Original Research

Published on 20 Sep 2024

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

in Pharmacology of Anti-Cancer Drugs

Qiong Jie
Yuanyuan Li
Li Jing
Jinjin Chen
Yang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1424980

4,998 views
7 citations

Original Research

Published on 31 Oct 2025

The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production

in Pharmacology of Anti-Cancer Drugs

Lingyun Ma
Hang Gong
Wei Sun
Jialing Deng
Qinghua Zhang
Jianzhao Niu
Huimin Sun
Xue Han
Tingting Du
Nina Xue

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1671798

1,440 views

Brief Research Report

Published on 10 Feb 2022

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

in Thoracic Oncology

Ning Zhou
Tong Li
Maoli Liang
Fan Ren
Hong Ni
Wei Liu
Tao Shi
Dongbo Xu
Qiusong Chen
Haonan Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.848779

5,174 views
17 citations

Original Research

Published on 21 Aug 2024

Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug

in Analytical Chemistry

Yonghong Zhu
Jisu Qin
Wenyi Wu
Liangliang Cai

Frontiers in Chemistry

doi 10.3389/fchem.2024.1450692

5,202 views
3 citations

Case Report

Published on 19 Nov 2024

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Kaidiriye Setiwalidi
Yimeng Li
Yuyan Ma
Zhanpeng Hao
Yujia Zhao
Yuxin Zhang
Xuan Liang
Tao Tian
Zhiping Ruan

Frontiers in Oncology

doi 10.3389/fonc.2024.1431908

2,771 views
2 citations

Original Research

Published on 12 Nov 2024

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

in Head and Neck Cancer

Fengli Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1491167

3,729 views
1 citation

Original Research

Published on 14 Sep 2022

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

in Cancer Molecular Targets and Therapeutics

Jeffrey J. Kooijman
Wilhelmina E. van Riel
Jelle Dylus
Martine B. W. Prinsen
Yvonne Grobben
Tessa J. J. de Bitter
Antoon M. van Doornmalen
Janneke J. T. M. Melis
Joost C. M. Uitdehaag
Yugo Narumi

Frontiers in Oncology

doi 10.3389/fonc.2022.953013

13,752 views
19 citations

Case Report

Published on 17 Apr 2023

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Tongyi Zhang
Hongwei Wang
Zhiwei Cai
Siqi Zhang
Chongyi Jiang

Frontiers in Oncology

doi 10.3389/fonc.2023.1078076

5,838 views
11 citations

Original Research

Published on 24 Jan 2025

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

in Pulmonary Medicine

Lei Wang
Yafei You
Wenzhuo He
Yu Hou
Lan Li
Li Wang
Chang Jiang
Jiahong Yi
Yaoxiong Xia
Liangping Xia

Frontiers in Medicine

doi 10.3389/fmed.2025.1467871

2,454 views
2 citations

Mini Review

Published on 30 May 2022

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Lu Zhao
Qingyun Mei
Yongchao Yu
Na Wang
Dou Zhang
Dongying Liao
Jinhui Zuo
Hongxia Xie
Yingjie Jia
Fanming Kong

Frontiers in Oncology

doi 10.3389/fonc.2022.894214

7,015 views

Case Report

Published on 12 Dec 2022

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

in Cancer Molecular Targets and Therapeutics

Margherita Nannini
Andrea Repaci
Gianluca Ricco
Manuela Ianni
Arber Golemi
Vincenzo Maiolo
Marco Ferrari
Filippo Natali
Elisa Lodi Rizzini
Fabio Monari

Frontiers in Oncology

doi 10.3389/fonc.2022.1042525

3,099 views
2 citations

Mini Review

Published on 14 Feb 2023

A comprehensive overview of the relationship between RET gene and tumor occurrence

in Cancer Genetics

Lu Zhao
Na Wang
Dou Zhang
Yingjie Jia
Fanming Kong

Frontiers in Oncology

doi 10.3389/fonc.2023.1090757

11,759 views
17 citations

Review

Published on 13 Dec 2022

Targeted therapy of RET fusion-positive non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Zixiong Shen
Binxu Qiu
Lin Li
Bo Yang
Guanghu Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1033484

14,973 views
19 citations

Case Report

Published on 26 Sep 2022

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

in Cancer Molecular Targets and Therapeutics

Sha-Sha Wang
Fang Wang
Zhen Zeng
Fang Gao
Huan-Huan Liu
Hui-Na Wang
Yi Hu
Hai-Feng Qin

Frontiers in Oncology

doi 10.3389/fonc.2022.929763

2,642 views
2 citations

Articles

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Re-challenging pralsetinib following recovery from pneumocystis jirovecii pneumonia in a lung cancer patient: a Case Report

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

A comprehensive overview of the relationship between RET gene and tumor occurrence

Targeted therapy of RET fusion-positive non-small cell lung cancer

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient